Laekna Inc. has announced the commencement of a Phase I single ascending dose (SAD) clinical study for LAE103, an internally discovered monoclonal antibody targeting ActRIIB. The study is being conducted in Australia and is designed as a randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE103 in healthy overweight or obese participants. According to the company, topline data from this study are expected to be available in the third quarter of 2026. No study results have been presented at this time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laekna Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251231-11971989), on December 31, 2025, and is solely responsible for the information contained therein.